On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2086-2091

  Gaudy Marqueste, C ^a   Carron, R ^b   Delsanti, C ^b   Loundou, A ^c   Monestier, S ^a   Archier, E ^a   Richard, M A ^a   Regis, J ^b   Grob, J J ^a  

^a UMR911 CRO2 ^*

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

BRAF inhibitors; brain metastasis; Gamma Knife radiosurgery; metastatic melanoma; radiosensitization

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RADIOSENSITIZING AGENT;

ADULT; ADVERSE DRUG REACTION; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN NEOPLASMS; FEMALE; HUMAN; MALE; MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; RADIOGRAPHY; RADIOSURGERY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION-SENSITIZING AGENTS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84925530184     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu266     Document Type: Article

References (21)

1. Davies, M.A., Liu, P., McIntyre, S., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117 (2011), 1687–1696.
2. Lippitz, B., Lindquist, C., Paddick, I., et al. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev 40 (2014), 48–59.
3. Gaudy-Marqueste, C., Regis, J.M., Muracciole, X., et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006), 809–816.
4. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
5. Hauschild, A., Grob, J.J., Demidov, L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
6. Long, G.V., Trefzer, U., Davies, M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 1087–1095.
7. Kefford, R.F., Maio, M., Arance, A., et al. Vemurafenib in melanoma patients with brain metastases: an open-label, single arm, phase 2 multicenter study. Pigment Cell Melanoma Res, 26, 2013, 964.
8. Ducassou, A., David, I., Delannes, M., et al. Radiosensitization induced by vemurafenib. Cancer Radiother 17 (2013), 304–307.
9. Peuvrel, L., Ruellan, A.L., Thillays, F., et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23 (2013), 879–881.
10. Boussemart, L., Boivin, C., Claveau, J., et al. Vemurafenib and radiosensitization. JAMA Dermatol 149 (2013), 855–857.
11. Anker, C.J., Ribas, A., Grossmann, A.H., et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31 (2013), e283–e287.
12. Narayana, A., Mathew, M., Tam, M., et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113 (2013), 411–416.
13. Rompoti, N., Schilling, B., Livingstone, E., et al. Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31 (2013), 3844–3845.
14. Flickinger, J.C., An integrated logistic formula for prediction of complications from radiosurgery. Int J Radiat Oncol Biol Phys 17 (1989), 879–885.
15. Kickingereder, P., Dorn, F., Blau, T., et al. Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. Radiat Oncol, 8, 2013, 52.
16. Raizer, J.J., Hwu, W.J., Panageas, K.S., et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neurooncol 10 (2008), 199–207.
17. Liew, D.N., Kano, H., Kondziolka, D., et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 114 (2011), 769–779.
18. Mori, Y., Kondziolka, D., Flickinger, J.C., et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42 (1998), 581–589.
19. Radbill, A.E., Fiveash, J.F., Falkenberg, E.T., et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101 (2004), 825–833.
20. Seung, S.K., Sneed, P.K., McDermott, M.W., et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am 4 (1998), 103–109.
21. Grob, J.J., Regis, J., Laurans, R., et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée. Eur J Cancer 34 (1998), 1187–1192.